论文部分内容阅读
目的：观察第二代质子泵抑制剂兰索拉唑治疗消化性溃疡的近期疗效。方法：104例消化性溃疡病人被分为两级。兰索拉唑组，54例，给予兰索拉唑30mg·d－1口服；奥美拉唑组，50例，给予20mg·d－1奥美拉唑口服，疗程4周。结果：两级溃疡4周愈合率分别为96．20％，88％，无统计学差异。但两组间3d疼痛消失率差异有显著性，P＜0．05。兰索拉唑组未见明显不良反应。结论：兰索拉唑是治疗消化性溃疡有效而安全的药物。
Objective: To observe the second-generation proton pump inhibitor lansoprazole in the treatment of peptic ulcer in the near future. Methods: 104 patients with peptic ulcer were divided into two levels. Lansoprazole group, 54 cases were given lansoprazole 30mg · d-1 omeprazole group, 50 cases given omeprazole 20mg · d-1 orally for 4 weeks. Results: The 4-week healing rates of two-stage ulcer were 96.20% and 88% respectively, with no significant difference. However, there was a significant difference in the disappearance rate of 3d pain between the two groups (P <0.05). Lansoprazole group showed no significant adverse reactions. Conclusions: Lansoprazole is an effective and safe drug for the treatment of peptic ulcer.